Deciphera pharmaceuticals, inc. (DCPH)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15
Net loss

-192,256

-99,854

-50,284

-25,940

-19,816

Adjustments to reconcile net loss to net cash flows used in operating activities:
Stock-based compensation expense

20,410

9,688

4,866

1,487

2,557

Depreciation expense

800

300

200

90

73

Non-cash interest expense

-

-

-

-

2,091

Loss on disposal of property and equipment

0

0

-10

-6

-

Net accretion of discounts on marketable securities

3,999

0

0

-

-

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

10,321

5,770

637

185

516

Operating lease assets

-958

-

-

-

-

Accounts payable

10,862

3,991

2,904

-187

1,176

Accrued expenses and other current liabilities

24,189

4,477

6,276

1,694

-

Operating lease liabilities

-319

-

-

-

-

Accrued expenses

-

-

-

-

1,160

Other assets

-

-

-

55

-6

Other long-term liabilities

350

368

13

-

-

Net cash flows used in operating activities

-149,296

-86,783

-36,702

-23,090

-13,269

Cash flows from investing activities:
Purchases of marketable securities

817,142

0

0

-

-

Maturities of marketable securities

261,216

0

0

-

-

Sales of marketable securities

100,780

0

0

-

-

Purchases of property and equipment

4,935

1,125

406

223

142

Increase in restricted investments

441

1,069

0

-

-

Net cash flows used in investing activities

-460,522

-2,194

-406

-223

-142

Cash flows from financing activities:
Proceeds from public offerings, net of underwriting discounts and commissions

432,400

185,933

129,112

-

-

Proceeds from issuance of convertible preferred shares

0

0

52,300

55,324

31,552

Proceeds from issuance of convertible notes payable to related parties

-

-

-

-

7,550

Repayment of notes payable to related party

1,294

187

187

198

186

Payments of public offering costs

620

674

4,395

104

-

Payments of convertible preferred share issuance costs

0

0

429

25

498

Proceeds from exercise of stock options

5,888

915

0

-

-

Net cash flows provided by financing activities

436,374

185,987

176,401

54,997

38,418

Net increase (decrease) in cash and cash equivalents

-173,444

97,010

139,293

31,684

25,007

Supplemental disclosure of cash flow information:
Cash paid for interest

67

84

95

106

117

Addition of operating lease asset included in accrued expenses and other current liabilities

562

0

0

-

-

Supplemental disclosure of non-cash investing and financing activities:
Amounts capitalized under build-to-suit lease transaction

0

11,900

0

-

-

Conversion of notes payable and accrued interest into convertible preferred shares

-

-

-

-

97,793

Conversion of member units into Series A convertible preferred shares

-

-

-

-

8,491

Gain on extinguishment of notes payable to related party

-

-

-

-

1,487

Property and equipment purchases included in accounts payable and accrued expenses and other current liabilities

661

0

78

-

-

Retirement of assets

217

0

0

-

-

Conversion of convertible preferred shares into common stock

0

0

244,538

-

-

Offering costs included in accounts payable and accrued expenses and other current liabilities

553

0

0

-

-